Macquarie Group LTD Arrowhead Pharmaceuticals, Inc. Transaction History

Macquarie Group LTD

$85.1 Billion
Q2 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 21, 2023	SELL	$28.0 - $40.56 $43,736 - $63,354	-1,562 Reduced 82.78%	325 $13,000
Q3 2022 Nov 14, 2022	SELL	$29.63 - $48.31 $17,215 - $28,068	-581 Reduced 23.54%	1,887 $100,000
Q1 2022 May 16, 2022	SELL	$39.62 - $69.97 $1.31 Million - $2.31 Million	-32,982 Reduced 93.04%	2,468 $114,000
Q4 2021 Feb 11, 2022	BUY	$58.09 - $82.51 $29,335 - $41,667	505 Added 1.45%	35,450 $2.35 Million
Q3 2021 Nov 12, 2021	SELL	$58.38 - $84.96 $1.58 Million - $2.29 Million	-27,009 Reduced 43.6%	34,945 $2.18 Million
Q2 2021 Aug 13, 2021	BUY	$62.15 - $90.32 $910,062 - $1.32 Million	14,643 Added 30.95%	61,954 $5.13 Million
Q1 2021 May 14, 2021	SELL	$61.35 - $90.47 $517,609 - $763,295	-8,437 Reduced 15.13%	47,311 $3.14 Million
Q4 2020 Feb 16, 2021	BUY	$43.82 - $85.37 $581,228 - $1.13 Million	13,264 Added 31.22%	55,748 $4.28 Million
Q3 2020 Nov 13, 2020	SELL	$33.21 - $51.27 $98,633 - $152,271	-2,970 Reduced 6.53%	42,484 $1.83 Million
Q2 2020 Aug 11, 2020	BUY	$26.12 - $43.27 $242,863 - $402,324	9,298 Added 25.72%	45,454 $1.96 Million
Q1 2020 May 15, 2020	BUY	$20.56 - $63.12 $453,471 - $1.39 Million	22,056 Added 156.43%	36,156 $1.04 Million
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $396,774 - $1.03 Million	14,100 New	14,100 $894,000
Q4 2018 Feb 15, 2019	SELL	$10.74 - $19.7 $2,148 - $3,940	-200 Closed	0 $0
Q3 2018 Nov 15, 2018	SELL	$14.0 - $20.3 $152,600 - $221,270	-10,900 Reduced 98.2%	200 $4,000
Q2 2018 Aug 14, 2018	BUY	$6.37 - $14.02 $70,707 - $155,622	11,100 New	11,100 $151,000
Q1 2018 May 11, 2018	SELL	$3.72 - $7.64 $124,248 - $255,176	-33,400 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$3.14 - $4.5 $104,876 - $150,300	33,400	33,400 $123,000

Others Institutions Holding ARWR

# of Institutions

295

Shares Held

92.3M

Call Options Held

1.33M

Put Options Held

549K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account